Nuvation Bio Inc Ordinary Shares - Class A NUVB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
-
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
-
Nuvation Bio to Participate in Upcoming Investor Conferences
-
Nuvation Bio Granted FDA Fast-Track Designation for Glioma Treatment
-
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
-
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
-
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
-
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
Trading Information
- Previous Close Price
- $5.56
- Day Range
- $5.03–5.66
- 52-Week Range
- $3.36–9.75
- Bid/Ask
- $5.15 / $5.23
- Shares Outstanding
- 351.12M
- Market Cap
- $1.80B
- Volume/Avg
- 15M / 6M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.31
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 305
- Website
- https://www.nuvationbio.com
Valuation
|
Metric
|
NUVB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.66 |
Price/Sales | 11.31 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NUVB
|
|---|---|
Quick Ratio | 7.98 |
Current Ratio | 8.37 |
Interest Coverage | −5.41 |
Quick Ratio
NUVB
Profitability
|
Metric
|
NUVB
|
|---|---|
Return on Assets (Normalized) | −16.94% |
Return on Equity (Normalized) | −34.33% |
Return on Invested Capital (Normalized) | −24.93% |
Return on Assets
NUVB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|n<H$$GY | LOCK|j!r&d | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|D@f>#! | LOCK|C!M&Z | $76B | |||
| Moderna Inc
MRNA
| LOCK|KNB@rb@ | LOCK|dD | $75B | |||
| argenx SE ADR
ARGX
| LOCK|SSb^vt! | LOCK|?xP | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@kpRyD | LOCK|c!> | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Y?@kBkF | LOCK|B$%<q | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|BWHN@K% | LOCK|RC>pc | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|>?q?x< | LOCK|H$ | $24B | |||
| Incyte Corp
INCY
| LOCK|&X?K@jw | LOCK|N@> | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|?y%@bw@ | LOCK|>mr | $15B |
United States